SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1116438
Abstract: Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia… read more here.
Keywords: mutations myelodysplastic; sf3b1 mutations; myelodysplastic syndromes; disease ... See more keywords